A Phase III Trial of SRS vs. HA-WBRT for Multiple (5-15) Metastases

A Phase III Trial of SRS vs. HA-WBRT for Multiple (5-15) Metastases

David Roberge, MD

THE SPEAKER

David Roberge, MD, is Full Professor at the University of Montreal and Adjunct professor at McGill University. He is a graduate of the McGill residency program in radiation oncology and completed post-residency fellowship at Stanford and St-Jude Children’s research hospital. He recently completed two terms as Head of the Department of radiation oncology at CHUM.

Based on his more than 20 years of experience, Dr. Roberge is the author of more than 140 peer-reviewed papers, book chapters and editorials. He is the founding editor of the Journal of the Canadian Association of Radiation Oncology and CNS editor for the ACR Journal Advisor. As a clinician scientist, his clinical research interests are broad but focus on intracranial tumors — most prominently those treated with radiosurgery. More recently, he has focused on technology in radiation oncology with an interest in deep learning and advanced imaging. He supervises numerous students and is currently the principal investigator of a second large international trial of radiosurgery for brain metastases.

David Roberge, MD

Watch the Recording

We'll email you a private link to watch the recording of this past, live webinar discussion.

First Name *

Last Name *

Email *

Hospital / Institution *

Role *

Country *

WHAT’S NEXT?

United States:
RECORDED: THU, APR 29, 8-8:30AM PDT

CHUM Research Center, Department of Radiation Oncology, University of Montreal, Quebec, Canada

We’re hosting ten other talks on the future of radiosurgery this fall. We’d like you to join us.